{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:23:45Z","timestamp":1772756625209,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.schres.2009.05.021","type":"journal-article","created":{"date-parts":[[2009,6,27]],"date-time":"2009-06-27T08:56:01Z","timestamp":1246092961000},"page":"56-64","source":"Crossref","is-referenced-by-count":19,"title":["Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms"],"prefix":"10.1016","volume":"113","author":[{"given":"C.M.","family":"Canuso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Bossie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2009.05.021_bib1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.jcp.0000222513.63767.de","article-title":"A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia","volume":"26","author":"Alvarez","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.schres.2009.05.021_bib2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1185\/030079906X132613","article-title":"Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form","volume":"22","author":"Conley","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.schres.2009.05.021_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/070674379704200105","article-title":"The varied outcomes of schizophrenia","volume":"42","author":"Davidson","year":"1997","journal-title":"Can. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2009.05.021_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2009.05.021_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00004850-200607000-00006","article-title":"Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone","volume":"21","author":"Gharabawi","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2009.05.021_bib6","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/schbul\/sbi035","article-title":"Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy","volume":"31","author":"Greenwood","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2009.05.021_bib7","doi-asserted-by":"crossref","unstructured":"Guy, W., 1976. 'Clinical global impressions', ECDEU Assessment Manual for Psychopharmacology (Revised, 1976 edn.; Rockville, Maryland: U.S. Department of Health and Human Services), 218\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"10.1016\/j.schres.2009.05.021_bib8","series-title":"Statistical Methods for Meta-analysis","author":"Hedges","year":"1985"},{"key":"10.1016\/j.schres.2009.05.021_bib9","unstructured":"Invega, P.I. 2007. Janssen, L.P. Titusville, NJ."},{"issue":"1\u20133","key":"10.1016\/j.schres.2009.05.021_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2009.05.021_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2009.05.021_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.jcp.0000236658.16286.25","article-title":"Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning","volume":"26","author":"Kinon","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2009.05.021_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0893-133X(99)00122-0","article-title":"Assessing the efficacy of treatments for the deficit syndrome of schizophrenia","volume":"22","author":"Kirkpatrick","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2009.05.021_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2009.05.021_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2009.05.021_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatry Scand."},{"issue":"3","key":"10.1016\/j.schres.2009.05.021_bib17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4088\/JCP.v68n0303","article-title":"A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia","volume":"68","author":"Lindenmayer","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2009.05.021_bib18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2009.05.021_bib19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study","volume":"62","author":"Marder","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2009.05.021_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies","volume":"60","author":"Meltzer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2009.05.021_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2009.05.021_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s004060170030","article-title":"Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia","volume":"251","author":"Moller","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2009.05.021_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02191543","article-title":"A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study","volume":"245","author":"Moller","year":"1995","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2009.05.021_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatry Scand."},{"issue":"2","key":"10.1016\/j.schres.2009.05.021_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","article-title":"Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia","volume":"161","author":"Nasrallah","year":"2008","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.schres.2009.05.021_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study","volume":"21","author":"Olie","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2009.05.021_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1185\/03007990802611919","article-title":"Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia","volume":"25","author":"Patrick","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.schres.2009.05.021_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1176\/appi.ajp.160.6.1133","article-title":"Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia","volume":"160","author":"Pickar","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2009.05.021_bib29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00406-005-0622-6","article-title":"Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2009.05.021_bib30","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.pnpbp.2007.02.014","article-title":"Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms","volume":"31","author":"Ruhrmann","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2009.05.021_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatry Scand. Suppl."},{"issue":"8","key":"10.1016\/j.schres.2009.05.021_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/hup.642","article-title":"Quetiapine has a direct effect on the negative symptoms of schizophrenia","volume":"19","author":"Tandon","year":"2004","journal-title":"Hum. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2009.05.021_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.154.4.466","article-title":"Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2009.05.021_bib34","first-page":"949","article-title":"Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia","volume":"4","author":"Turkoz","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996409002370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996409002370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T22:52:24Z","timestamp":1633647144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996409002370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0920996409002370"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2009.05.021","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}